Corindus Vascular Robotics (NYSEMKT: CVRS) has recently received a number of price target changes and ratings updates:

  • 9/7/2017 – Corindus Vascular Robotics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.00 price target on the stock. According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
  • 9/6/2017 – Corindus Vascular Robotics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
  • 8/29/2017 – Corindus Vascular Robotics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.00 price target on the stock. According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
  • 8/28/2017 – Corindus Vascular Robotics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
  • 8/25/2017 – Corindus Vascular Robotics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/23/2017 – Corindus Vascular Robotics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/23/2017 – Corindus Vascular Robotics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.75 price target on the stock. According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
  • 8/22/2017 – Corindus Vascular Robotics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
  • 8/16/2017 – Corindus Vascular Robotics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/10/2017 – Corindus Vascular Robotics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/9/2017 – Corindus Vascular Robotics was given a new $3.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/4/2017 – Corindus Vascular Robotics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/24/2017 – Corindus Vascular Robotics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/17/2017 – Corindus Vascular Robotics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/11/2017 – Corindus Vascular Robotics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.00 price target on the stock. According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) opened at 1.63 on Friday. The stock has a 50 day moving average of $1.70 and a 200-day moving average of $1.42. Corindus Vascular Robotics Inc has a one year low of $0.40 and a one year high of $2.25. The stock’s market capitalization is $305.29 million.

Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $2.26 million during the quarter, compared to the consensus estimate of $3.10 million. Corindus Vascular Robotics had a negative return on equity of 94.27% and a negative net margin of 372.63%. Equities analysts forecast that Corindus Vascular Robotics Inc will post ($0.21) earnings per share for the current year.

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.